Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nymox Pharm Corp (NYMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 196,755
  • Shares Outstanding, K 50,450
  • Annual Sales, $ 280 K
  • Annual Income, $ -13,110 K
  • 36-Month Beta 0.87
  • Price/Sales 696.35
  • Price/Cash Flow 0.00
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.78 +2.12%
on 07/27/17
4.69 -17.70%
on 06/30/17
-0.31 (-7.43%)
since 06/27/17
3-Month
3.28 +17.68%
on 05/02/17
4.97 -22.33%
on 04/28/17
-0.87 (-18.39%)
since 04/27/17
52-Week
1.62 +138.27%
on 08/10/16
5.79 -33.33%
on 08/25/16
-0.10 (-2.53%)
since 07/27/16

Most Recent Stories

More News
Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce statistically significant clinical trial results showing that the Company's prostate enlargement (BPH) and prostate cancer drug Fexapotide...

NYMX : 3.84 (-1.54%)
NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries,...

NYMX : 3.84 (-1.54%)
Pacific Biosciences of California and Nymox Pharmaceutical Move Up On Bullish Product Environments

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Both companies had active trading sessions on Wednesday, as news of insider buying and optimistic product forecasts drew attention to the two biotech stocks....

NYMX : 3.84 (-1.54%)
PACB : 3.28 (-1.50%)
Nymox Provides Update on Fexapotide Development

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) provided an update today on the Company's development activities for Fexapotide Triflutate, its new drug for prostate enlargement. The Company is very pleased...

NYMX : 3.84 (-1.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Nymox Pharmaceutical Corporation is engaged in the research and development of drugs and diagnostic products. The company offers products such as AlzheimAlert, NicAlert and TobacAlert tests. It markets its products primarily in the United States, Canada, and Europe. Nymox Pharmaceutical Corporation is...

See More

Support & Resistance

2nd Resistance Point 3.97
1st Resistance Point 3.94
Last Price 3.84
1st Support Level 3.86
2nd Support Level 3.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.